Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.14B | $1.05B | $966.5M | $972.3M | $928.0M | $850.7M | $872.5M | $741.7M |
| Cost of revenue | $829.5M | $763.8M | $697.2M | $704.7M | $665.9M | $605.4M | $633.4M | $566.3M |
| Gross profit | $312.8M | $283.6M | $269.3M | $267.7M | $262.1M | $245.3M | $239.1M | $175.4M |
| Gross margin | 27.4% | 27.1% | 27.9% | 27.5% | 28.2% | 28.8% | 27.4% | 23.6% |
| R&D | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating income | −$7.0M | −$15.2M | −$40.2M | −$18.3M | −$10.4M | $11.3M | −$14.8M | −$69.5M |
| EBITDA | $10.9M | −$42.9M | −$28.7M | −$14.2M | $2.0M | $25.3M | $2.0M | −$49.1M |
| Net income | −$26.2M | −$42.9M | −$76.5M | −$43.9M | −$53.3M | −$28.3M | −$45.6M | −$101.1M |
| Net margin | -2.3% | -4.1% | -7.9% | -4.5% | -5.7% | -3.3% | -5.2% | -13.6% |
| EPS (diluted) | -0.80 | -1.32 | -2.30 | -1.31 | -1.59 | -0.82 | -1.29 | -2.77 |
Annual figures · source: Financial Modeling Prep
No one on the platform currently holds IVC.
No tracked institution reports a position in IVC as of their last filing.
No one on the platform has traded IVC yet.
| $42M |
| — |
| FRLNFreeline Therapeutics Holdings plc | $6.49 | +0.15% | $28M | — |
| LSBLakeShore Biopharma Co., Ltd | $0.63 | +0.00% | $26M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.